Dosage Forms

Articles

The new lab near Continuus Pharmaceutical’s current facilities in Massachusetts will expand the company’s process development capabilities to high-potency drugs.

Continuus Pharmaceuticals Opens Process Development Lab

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.

Assessing Risk and Production of Potent Substances

The company will expand its micronization abilities for highly potent drug compounds through this investment. 

Catalent to Invest $10 Million to Increase Isolator Capabilities at US and UK Sites

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

HPAPI Complexity Prompts New Delivery Mechanisms

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks? 

Formulating an ADC Development Solution

Editor of Pharmaceutical Technology Europe

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.


Keeping Toxicity to a Minimum

Jennifer Markarian is manufacturing editor of Pharmaceutical Technology.

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

Best Practices in Handling HPAPIs

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

Majority of High-Containment CMO Facilities Located in 5EU and Switzerland, Notes GlobalData

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.


In Safe Hands

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Highly Potent Drugs